Join
Live feed
·
PRReleasevia Quantisnow
Kronos Bio Inc. logo

Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

ByQuantisnow·Wall Street's wire, on your screen.
KRON· Kronos Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRON (Kronos Bio Inc.) and more on Quantisnow.